Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects

Vaccine

Volumn 33, Issue 39, 2015, Pages 5225-5234

  Frey, Sharon E ^a   Wald, Anna ^b   Edupuganti, Srilatha ^c   Jackson, Lisa A ^d   Stapleton, Jack T ^e   Sahly, Hana El ^f   El Kamary, Samer S ^g   Edwards, Kathryn ^h   Keyserling, Harry ^c   Winokur, Patricia ^e   Keitel, Wendy ^f   Hill, Heather ⁱ   Goll, Johannes B ⁱ   Anderson, Edwin L ^a   Graham, Irene L ^a   Johnston, Christine ^b   Mulligan, Mark ^c   Rouphael, Nadine ^c   Atmar, Robert ^f   Patel, Shital ^f   Chen, Wilbur ^k   Kotloff, Karen ^k   Creech, C Buddy ^h   Chaplin, Paul ^j   Belshe, Robert B ^a   more..

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CENTER FOR HEALTH STUDIES   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^h VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

ⁱ EMMES CORPORATION   (United States)

^j University of Maryland School of Medicine Center for Vaccine Development   (United States)

^k Bavarian Nordic GmbH   (Germany)

more..

Author keywords

ELISA; IMVAMUNE; Intradermal; Lyophilized; MVA; NCT00914732; Plaque reduction neutralizing antibody; Smallpox; Subcutaneous; Vaccinia na ve; Variola

Indexed keywords

ANTIBODY; MODIFIED VACCINIA ANKARA VACCINE; SMALLPOX VACCINE; UNCLASSIFIED DRUG; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ABNORMAL LABORATORY RESULT; ADULT; ANTIBODY BLOOD LEVEL; APPENDICITIS; ARTICLE; BACKACHE; COLITIS; DISEASE SEVERITY; DRUG FORMULATION; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEMALE; FEVER; FREEZE DRYING; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; ISCHEMIC COLITIS; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN DISCOLORATION; VACCINATION; ADOLESCENT; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHEMISTRY, PHARMACEUTICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INJECTIONS, INTRADERMAL; INJECTIONS, SUBCUTANEOUS; MALE; SMALLPOX VACCINE; YOUNG ADULT;

EID: 84941741642     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.06.075     Document Type: Article

References (40)

1. Fenner F., Henderson D.A., Arita I., Jezek Z., Ladnyi I.D. Smallpox and its eradication 1988, 1-1460. World Health Organization, Geneva.
2. Shchelkunov S.N. Emergence and reemergence of smallpox: the need in development of a new generation smallpox vaccine. Vaccine 2011, 29(Suppl. 4):D49-D53.
3. Acambis Inc. ACAM2000TM smallpox vaccine, vaccines and related biological products advisory committee (VRBPAC) briefing document April 18 2007, http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4292b2-02.pdf.
4. Mayr A., Hochstein-Mintzel V., Stickl H. Passage history, properties, and use of attenuated vaccinia virus strain MVA. Infection 1975, 3:6-14.
5. Suter M., Meisinger-Henschel C., Tzatzaris M., Hülsemann V., Lukassen S., Wulff N.H., et al. Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain. Vaccine 2009, 27:7442-7450.
6. Walsh S.R., Wilck M.B., Dominguez D.J., Zablowsky E., Bajimaya S., Gagne L.S., et al. Safety and immunogenicity of modified vaccinia ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. J Infect Dis 2013, 207:1888-1897.
7. Greenberg R.N., Overton E.T., Haas D.W., Frank I., Goldman M., von Krempelhuber A., et al. Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects. J Infect Dis 2013, 207:749-758.
8. ®. Vaccine 2010, 28:1209-1216.
9. ® challenge. Vaccine 2007, 25:8562-8573.
10. Mayr A., Stickl H., Müller H.K., Danner K., Singer H. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defense mechanism. Zentralbl Bakteriol 1978, 167:375-390.
11. Stickl H., Hochstein M. Intracutaneous smallpox vaccination with a weak pathogenic vaccinia virus (MVA virus). Münch Med Wochenschr 1971, 113:1149-1153.
12. Schroeter W., Stickl H., Idel H., Schlipkoter H.A. MVA-vaccine in primovaccination against smallpox after the age of three. Zentralbl Bakteriol Mikrobiol Hyg B 1980, 171:309-319.
13. Hoffmann F., Poduschnik H. Richter KH Local reaction and neutralization test in smallpox. MMW Munshener Med Wochenschr 1978, 120:989-992.
14. Moorthy V.S., Imoukhuede E.B., Keating S., Pinder M., Webster D., Skinner M.A., et al. Phase I evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J Infect Dis 2004, 189:2213-2219.
15. Cebere I., Dorrell L., McShane H., Simmons A., McCormack S., Schmidt C., et al. Phase I clinical safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 2006, 24:417-425.
16. McShane H., Pathan A.A., Sander C.R., Keating S.M., Gilbert S.C., Huygen K., et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycrobial immunity in humans. Nat Med 2004, 10:1240-1244.
17. Moorthy V.S., Imoukhuede E.B., Milligan P., Bojang K., Keating S., Kaye P., et al. A randomized, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med 2004, 1:128-136.
18. Moorthy V.S., Pinder M., Reece W.H., Watkins K., Atabani S., Hannan C., et al. Safety and immunogenicity of DNA/Modified vaccinia Ankara malaria vaccination in African adults. J Infect Dis 2008, 188:1239-1244.
19. Mwau M., Cebere I., Sutton J., Chikoti P., Winstone N., Wee E.G., et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 2004, 85:911-919.
20. Peters B.S., Jaoko W., Vardas E., Panayotakopoulos G., Fast P., Schmidt C., et al. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 2007, 25:2120-2127.
21. Webster D.P., Dunachie S., McConkey S., Poulton I., Moore A.C., Walther M., et al. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in nonimmune volunteers. Vaccine 2006, 24:3026-3034.
22. Belshe R.B., Newman F.K., Cannon J., Duane C., Treanor J., Van Hoecke C., et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004, 351:2286-2294.
23. Coleman P.J., Shaw F.E., Serovich J., Hadler S.C., Margolis H.S. Intradermal hepatitis B vaccination in a large hospital employee population. Vaccine 1991, 9:723-727.
24. Kenney R.T., Frech S.A., Muenz L.R., Villar C.P., Glenn G.M. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004, 351:2295-2301.
25. Henderson E.A., Louie T.J., Ramotar K., Ledgerwood D., Hope K.M., Kennedy A. Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers. Infect Control Hosp Epidemiol 2000, 21:264-269.
26. Sabchareon A., Chantavanich P., Pasuralertsakul S., Pojjaroen-Anat C., Prarinyanupharb V., Attanath P., et al. Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified Vero cell rabies vaccine. Pediatr Infect Dis J 1998, 17:1001-1007.
27. Seaman M.S., Wilck M.B., Baden L.R., Walsh S.R., Grandpre L.E., Devoy C., et al. Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax. J Infect Dis 2010, 201:1353-1360.
28. Wilck M.B., Seaman M.S., Baden L.R., Walsh S.R., Grandpre L.E., Devoy C., et al. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration. J Infect Dis 2010, 201:1361-1370.
29. Nelson E.A.S., Lam H.S., Choi K.C., HO W.C.S., Fung L.W.E., Cheng F.W.T. A pilot randomized study to assess immunogenicity, reactogenticity, safety and tolerability of two human papillomavirus vaccines administered intramuscularly and intradermally to females aged 18-26 years. Vaccine 2013, 31:3452-3460.
30. Iacono-Connors L.C., Novak J., Rossi C., Mangiafico J., Ksiazek T. Enzyme-linked immunosorbent assay using a recombinant baculovirus-expressed Bacillus anthracis protective antigen (PA): measurement of human anti-PA antibodies. Clin Diagn Lab Immunol 1994, 1:78-82.
31. Newman F.K., Frey S.E., Blevins T.P., Mandava M., Bonifacio A., Yan L., et al. Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine. J Clin Microbiol 2003, 41:3154-3157.
32. Wang W.W.B., Mehrotra D.V., Chan I.S.F., Heyse J.F. Statistical considerations for noninferiority/equivalence trials in vaccine development. J Biopharm Stat 2006, 16:429-441.
33. Diez-Domingo J., Gurtman A., Bernaola E., Gimenez-Sanchez F., Martinon-Torres F., Pineda-Solas V., et al. Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain. Vaccine 2013, 31:5486-5494.
34. Frenck R.W., Gurtman A., Rubinoc J., Smith W., van Cleeffe M., Jayawardene D., et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol 2012, 19:1296-1303.
35. ® smallpox vaccine using different strategies for a post event scenario. Vaccine 2013, 31:3025-3033.
36. Sarkar J.K., Mitra A.C., Mukherjee M.K. The minimum protective level of antibodies in smallpox. Bull World Health Organ 1975, 52:307-311.
37. Mack T.M., Noble J., Thomas D.B. A prospective study of serum antibody and protection against smallpox. Am J Trop Med Hyg 1972, 21:214-218.
38. Kennedy R.B., Lane J.M., Henderson D.A., Poland G.A. Smallpox and vaccinia. Vaccines 2013, 718-745. Saunders, Elsevier Inc., Philadelphia, PA. S. Plotkin, W. Orenstein, P. Offit (Eds.).
39. Damon I.K., Davidson W.B., Hughes C.M., Olson V.A., Smith S.K., Holman R.C., et al. Evaluation of smallpox vaccines using variola neutralization. J Gen Virol 2009, 90:1962-1966.
40. Hughes C., Newman F., Davidson W., Olson V., Smith S., Holman R., et al. Analysis of variola and vaccinia neutralization assays for smallpox vaccines. Clin Vaccine Immunol 2012, 19:1116-1118.